Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers

Carcinogenesis

Volumn 34, Issue 1, 2013, Pages 109-112

  Liao, Linda M ^a   Weinstein, Stephanie J ^a   Pollak, Michael ^b   Li, Zhen ^b   Virtamo, Jarmo ^c   Albanes, Demetrius ^a   Chow, Wong Ho ^a   Purdue, Mark P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALPHA TOCOPHEROL; BETA CAROTENE; LEPTIN; RESISTIN;

ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK REDUCTION; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADIPOKINES; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FINLAND; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SMOKING;

EID: 84872131010     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs322     Document Type: Article

References (49)

1. Chow, W.H. et al. (2010) Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol., 7, 245-257.
2. McLaughlin, J.K., et al. (2006) Renal cancer. In Schottenfeld, D. and Fraumeni, J.F. (eds.), Cancer Epidemiology and Prevention. Oxford University Press, New York.
3. Chow, W.H. et al. (2000) Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med., 343, 1305-1311.
4. Bjøge, T. et al. (2004) Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am. J. Epidemiol., 160, 1168-1176.
5. Setiawan, V.W. et al. (2007) Risk factors for renal cell cancer: the multiethnic cohort. Am. J. Epidemiol., 166, 932-940.
6. Reeves, G.K., et al. (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ, 335, 1134.
7. Luo, J., et al. (2007) Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States). Am. J. Epidemiol., 166, 752-759.
8. Flaherty, K.T. et al. (2005) A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control, 16, 1099-1106.
9. Adams, K.F. et al. (2008) Body size and renal cell cancer incidence in a large US cohort study. Am. J. Epidemiol., 168, 268-277.
10. Calle, E.E. et al. (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer, 4, 579-591.
11. Fischer-Posovszky, P. et al. (2007) Endocrinology of adipose tissue - an update. Horm. Metab. Res., 39, 314-321.
12. Lago, F. et al. (2007) The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev., 18, 313-325.
13. Tilg, H. et al. (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol., 6, 772-783.
14. Stolzenberg-Solomon, R.Z. et al. (2008) Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am. J. Epidemiol., 168, 1047-1055.
15. Stattin, P. et al. (2003) Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol. Rep., 10, 2015-2021.
16. Hou, W.K. et al. (2007) Adipocytokines and breast cancer risk. Chin. Med. J., 120, 1592-1596.
17. Arita, Y. et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun., 257, 79-83.
18. Cnop, M. et al. (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 46, 459-469.
19. Kadowaki, T. et al. (2005) Adiponectin and adiponectin receptors. Endocr. Rev., 26, 439-451.
20. Hardie, D.G. (2008) AMPK: a key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. (Lond)., 32 Suppl 4, S7-12.
21. Viollet, B., et al. (2011) AMP-activated protein kinase and metabolic control. Handb. Exp. Pharmacol., 203, 303-330.
22. Zakikhani, M. et al. (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev. Res. (Phila)., 1, 369-375.
23. Considine, R.V. et al. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med., 334, 292-295.
24. Ruhl, C.E. et al. (2001) Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am. J. Clin. Nutr., 74, 295-301.
25. Garofalo, C. et al. (2006) Leptin and cancer. J. Cell. Physiol., 207, 12-22.
26. Housa, D. et al. (2006) Adipocytokines and cancer. Physiol. Res., 55, 233-244.
27. Renehan, A.G. et al. (2008) Obesity and cancer: pathophysiological and biological mechanisms. Arch. Physiol. Biochem., 114, 71-83.
28. Curat, C.A. et al. (2006) Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia, 49, 744-747.
29. Hivert, M.F. et al. (2008) Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J. Clin. Endocrinol. Metab., 93, 3165-3172.
30. McTernan, P.G. et al. (2003) Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J. Clin. Endocrinol. Metab., 88, 6098-6106.
31. Adeghate, E. (2004) An update on the biology and physiology of resistin. Cell. Mol. Life Sci., 61, 2485-2496.
32. Calabro, P. et al. (2004) Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation, 110, 3335-3340.
33. Spyridopoulos, T.N., et al. (2009) Inverse association of leptin levels with renal cell carcinoma: results from a case-control study. Hormones (Athens), 8, 39-46.
34. Spyridopoulos, T.N., et al. (2007) Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int. J. Cancer, 120, 1573-1578.
35. ATBC Cancer Prevention Study Group (1994) The alpha-tocopherol, betacarotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann. Epidemiol., 4, 1-10.
36. Korhonen, P. et al. (2002) The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol., 41, 381-388.
37. Kelesidis, I. et al. (2006) Adiponectin and cancer: a systematic review. Br. J. Cancer, 94, 1221-1225.
38. Wang, Y. et al. (2005) Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J. Biol. Chem., 280, 18341-18347.
39. Hug, C. et al. (2004) T-cadherin is a receptor for hexameric and highmolecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. U.S.A., 101, 10308-10313.
40. Renehan, A.G. et al. (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 371, 569-578.
41. Pinthus, J.H. et al. (2008) Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur. Urol., 54, 866-873.
42. Miyoshi, Y. et al. (2003) Association of serum adiponectin levels with breast cancer risk. Clin. Cancer Res., 9, 5699-5704.
43. Mantzoros, C. et al. (2004) Adiponectin and breast cancer risk. J. Clin. Endocrinol. Metab., 89, 1102-1107.
44. Cust, A.E. et al. (2007) Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J. Clin. Endocrinol. Metab., 92, 255-263.
45. Petridou, E. et al. (2003) Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J. Clin. Endocrinol. Metab., 88, 993-997.
46. Dal Maso, L. et al. (2004) Circulating adiponectin and endometrial cancer risk. J. Clin. Endocrinol. Metab., 89, 1160-1163.
47. Wei, E.K. et al. (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J. Natl. Cancer Inst., 97, 1688-1694.
48. Phillips, S.A. et al. (2010) Mechanisms of adiponectin regulation and use as a pharmacological target. Curr. Opin. Pharmacol., 10, 676-683.
49. Yamauchi, T. et al. (2008) Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int. J. Obes. (Lond)., 32 (suppl. 7), S13-S18.